Frontiers in Pharmacology (Jan 2021)

Phytosterols: From Preclinical Evidence to Potential Clinical Applications

  • Bahare Salehi,
  • Cristina Quispe,
  • Javad Sharifi-Rad,
  • Javad Sharifi-Rad,
  • Natália Cruz-Martins,
  • Natália Cruz-Martins,
  • Natália Cruz-Martins,
  • Manisha Nigam,
  • Abhay Prakash Mishra,
  • Dmitryi Alexeevich Konovalov,
  • Valeriya Orobinskaya,
  • Ibrahim M. Abu-Reidah,
  • Wissam Zam,
  • Farukh Sharopov,
  • Tommaso Venneri,
  • Raffaele Capasso,
  • Wirginia Kukula-Koch,
  • Anna Wawruszak,
  • Wojciech Koch

DOI
https://doi.org/10.3389/fphar.2020.599959
Journal volume & issue
Vol. 11

Abstract

Read online

Phytosterols (PSs) are plant-originated steroids. Over 250 PSs have been isolated, and each plant species contains a characteristic phytosterol composition. A wide number of studies have reported remarkable pharmacological effects of PSs, acting as chemopreventive, anti-inflammatory, antioxidant, antidiabetic, and antiatherosclerotic agents. However, PS bioavailability is a key issue, as it can be influenced by several factors (type, source, processing, preparation, delivery method, food matrix, dose, time of administration into the body, and genetic factors), and the existence of a close relationship between their chemical structures (e.g., saturation degree and side-chain length) and low absorption rates has been stated. In this sense, the present review intends to provide in-depth data on PS therapeutic potential for human health, also emphasizing their preclinical effects and bioavailability-related issues.

Keywords